Cabazitaxel (CBZ) is approved for docetaxel-resistant castration-resistant prostate cancer (CRPC). However, efficacy of CBZ for CRPC is limited and there are no effective treatments for CBZ-resistant CRPC. In order to investigate the CBZ-resistant mechanism, the establishment of a CBZ-resistant cell line is urgently needed.
| INTRODUCTION
Prostate cancer is the most prevalent cancer and second leading cause of cancer among men in the USA. 1, 2 The most common treatment for metastatic prostate cancer is androgen deprivation therapy using luteinizing hormone-releasing hormone analogues and nonsteroidal antiandrogens. Although metastatic prostate cancer initially responds well to androgen deprivation therapy, most of the patients acquire resistance to this therapy and develop CRPC.
Treatment options for CRPC have expanded with the addition of next-generation antiandrogens such as abiraterone acetate and enzalutamide, autologous immunotherapy with sipuleucel-T, internal radiotherapy treatment with radium223, and chemotherapeutic agents. 3 The current standard first-line chemotherapy for metastatic CRPC is DOC. Cabazitaxel was approved by the US FDA for docetaxel-resistant CRPC in 2010. However, the duration of the response to CBZ is limited to only several months for DOC-resistant CRPC 4 and there are no effective treatments for CBZ-resistant CRPC.
The taxanes exert antitumor effects by stabilizing microtubules, thereby blocking cells in the G 2 /M phase of the cell cycle. There have been several reports on prostate cancer cell line models that showed resistance to PAC or DOC. 5, 6 One of the mechanisms of PAC/DOC resistance is P-gp drug transporter. 7 Cabazitaxel was found by screening for a taxane with poor affinity for P-gp and effective for PAC/DOC resistant CRPC. 8 However, acquired CBZ resistance is clinically inevitable and the mechanisms of CBZ resistance are still unclear.
In order to analyze the mechanisms of CBZ resistance, we incubated CRPC cell lines with gradually increasing concentrations of CBZ and established CBZ-resistant CRPC cell lines. We analyzed the gene expression profiles of the cell line and identified a therapeutic target for CBZ-resistant CRPC.
| MATERIALS AND METHODS

| Reagents
We used rabbit mAb for pan AKT, phosphorylated AKT (Ser473) (Cell Signaling Technology, Danvers, MA, USA), rabbit polyclonal antibody for ERK 1/2, phosphorylated ERK 1/2 (Thr202/Tyr204) (Cell Signaling Technology), and mouse mAb for α-tubulin and β-actin (Sigma-Aldrich, St. Louis, MO, USA). WST reagents (Takara Bio, Kyoto, Japan) were also used.
| Cell lines and culture
The CRPC cell lines DU145 and PC3 were obtained from ATCC (Manassas, VA, USA). To develop resistance, DU145 and PC3 cells were grown in RPMI-1640 supplemented with 10% FBS containing CBZ at 37°C in a humidified 5% CO 2 atmosphere. Starting at a concentration of 0.3 nmol/L, the exposure dose was increased by 30%-50% until it reached a final concentration of 3 nmol/L. These cells were passaged after reaching confluence over a 24-month period.
These new cell lines were named DU145CR and PC3CR. Parental DU145 and PC3 cells were cocultured without drug for the 2 years as control cells. DU145, PC3, DU145CR, and PC3CR were routinely maintained in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Dainippon Pharmaceutical, Tokyo, Japan) at 37°C in a humidified 5% CO 2 atmosphere, and further examinations were carried out after 3 months without CBZ exposure.
| WST cell viability assay
DU145, PC3, DU145CR, and PC3CR cells were seeded on 96-well plates, allowed to attach for 24 hours, and then treated with different concentrations of CBZ, PD184352 (Wako, Osaka, Japan), and NVP-BEZ235 (BEZ235) (kindly provided by Novartis, Basel, Switzerland) for 48 hours. At the end of the incubation period, WST reagents were added to each well and the cells were incubated for 1 hour. Cell viability was estimated by colorimetry by reading color intensity in a plate reader at 570 nm. 
| Murine xenograft prostate cancer model
| Immunohistochemistry
We immunostained the xenograft tumors treated by CBZ. Sections were applied and incubated with secondary antibodies conjugated to peroxidase labeled dextran polymer. The immunoreaction was visualized using diaminobenzidine and counterstaining was undertaken with 10% hematoxylin. The percent of cancer cells with nuclei stained for Ki67 (the Ki67 index) was calculated for each section based on more than 1000 cancer cell nuclei. Apoptosis was measured by TUNEL assay using an in situ apoptosis detection kit (Takara Bio).
For the TUNEL assay, we used control slides from the apoptosis detection kit as a positive control, and control slides without terminal deoxynucleotidyl transferase enzyme as a negative control. The average number of stained cells was counted and the apoptosis index was calculated as the average number in 5 areas in a 400× field.
| Immunofluorescence
To measure immunofluorescence, 1 × 10 4 cells were seeded on 14- and visualized by confocal microscopy.
| Microarray gene expression analysis
Total RNA was isolated from cell lines using an RNeasy Mini kit (Qia- intensities were stored as cell intensity files, and the files were normalized with the robust multichip average method. These datasets were filtered, and genes with an absolute fold change ≥2 or ≤0.5
were identified as being differentially expressed. Gene ontology analysis to identify biological processes likely related with CBZ resistance was carried out in DAVID tools. 9 The analysis was undertaken using the FAC module set to high stringency. The FAC enrichment score (−log 10 P-values/n) for each cluster was graphed. The enrichment score provides an indication of the biological significance of the clusters.
| Cell extracts and western blots
Whole cell extracts were obtained using RIPA buffer composed of 50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1% NP-40, 0.5% deoxycholate, and 0.1% SDS and containing protease inhibitors. For western blots, 50 mg of total protein was separated by SDS-PAGE on 12.5% acrylamide gel and transferred to a nitrocellulose membrane. Blots were incubated with peroxidase labeled secondary antibody (Dako; Agilent Technologies). Signals were detected using enhanced chemiluminescence reagents with a detection system (Pierce ™ ECL Plus Western Blotting Substrate; Thermo Fisher Scientific) and analyzed. Intensity was quantified using an LAS 3000 system (Fujifilm, Tokyo, Japan).
| Real-time quantitative PCR
Total RNA was isolated using an RNeasy Mini kit (Qiagen, Hilden, Germany), and the quantity and quality were evaluated by spectrophotometry. Reverse transcription of RNA to cDNA was carried out using PrimeScript RT reagent Kit with gDNA Eraser (Takara Bio).
The reaction mixture (1 μL) was then used as a template in a Taq 
| Statistics
Experiments were carried out with 3 or more replicates. Statistical analysis was undertaken using Student's t test and the Tukey-Kramer method for multiple comparison test, with P < .05 considered significant.
| RESULTS
| Establishment of CBZ-resistant cell lines
We incubated DU145 and PC3 cells with gradually increasing concentrations of CBZ for 24 months and established CRPC sublines, which were named DU145CR and PC3CR ( Figure 1A ). DU145CR
and PC3CR had significantly more resistance to CBZ than DU145 and PC3 in WST assay ( Figures 1B and S1A 
| Enhancement of MAPK signaling as a potential therapeutic target for CBZ-resistant CRPC
We investigated the status of MAPK signaling and PI3K signaling as cell cycle-related pathways by western blotting. Phosphorylation of ERK was enhanced in DU145CR cells, whereas AKT phosphorylation was not ( Figure 4A,B) . DU145CR xenograft tumors also had higher levels of phosphorylate ERK than DU145 tumors ( Figure S4 ). No significant differences of P-gp expression were detected between DU145 and DU145CR cells ( Figure S5 ). To determine whether enhancement of ERK signaling was a potential therapeutic target for CBZ-resistant CRPC, we examined and compared the efficacy of the MEK1/2 inhibitor PD184352 in DU145 and DU145CR cells. The relative viability of DU145CR cells treated with PD184352 was significantly less than that of DU145 cells ( Figure 4C ). Phosphorylation of ERK was inhibited in DU145CR 24 hours after treatment with PD184352 ( Figure 4D ,E).
| DISCUSSION
In this study, we describe the gene expression profiles and cell cycle patterns of a CBZ-resistant cell line originally established in our laboratory and identify enhanced ERK signaling as a therapeutic target for CBZ-resistant CRPC. A previous report described cross-resistance to CBZ of DOC-resistant CRPC cell lines. 10 On this point, we also reported the sensitivity of a DOC-resistant cell line, C4-2AT6, to CBZ. 11 Contrary to the report by Lombard et al, C4-2AT6 had higher sensitivity for CBZ than the DOC-sensitive cell line C4-2 in our study. In this study, we report the establishment of CBZ-resistant cell lines by continuously exposing taxane-naïve cell lines to CBZ.
Our established CBZ-resistant cell lines derived from DOC-naïve ones had no resistance to DOC ( Figure S3 ). This result suggests that DOC might be useful in the post-CBZ setting although, based on findings from the FIRSTANA clinical trial, CBZ is currently not going to be used before DOC. The ERK pathway is evolutionarily conversed and regulates cell proliferation, growth, apoptosis, and differentiation. Enhancement of ERK signaling has been reported to be a risk factor for various cancers such as pancreas, lung, or colorectal carcinomas. [13] [14] [15] However, the relationship between ERK signaling and CBZ-resistant CRPC progression is still unclear. In this study, the CBZ-resistant cell line showed enhancement of ERK signaling and an MEK inhibitor was effective in the cell line, suggesting that ERK signaling is also involved in CBZ-refractory CRPC.
Prostate cancer patients are often reported to be PTEN deficient, 16 so PI3K/AKT signaling has attracted attention as a prostate cancer risk and a therapeutic target. We also reported that enhancement of PI3K/AKT signaling was related with castration-refractory and DOC-resistant CRPC. 17, 18 Enhancement of PI3K/AKT signaling We previously reported on cisplatin-resistant urothelial cancer cell lines, which had an IC 50 3 times higher than parental cells. 19 Xenograft tumors of these cell lines also grew to twice the size of that of their parental cell lines. In addition, some researchers have reported that cell lines derived from chemoresistant cancer patients had an IC 50 2-3 times higher than those from chemotherapy naïve cancer patients. [20] [21] [22] As can be surmised from the above, the observable degree of resistance may be different among in vitro, in vivo, and clinical settings. were detected in the cell lines, so ERK or PI3K/AKT could be therapeutic targets for CBZ-resistant CRPC. 
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